How can we develop new drugs and get them to people more quickly? At the MRC’s Open Council meeting last week, a lot of the discussion focused on how the changing environment for the pharmaceutical industry means we need new models for drug discovery, and much closer working between academic and industry researchers. Katherine Nightingale rounds up the discussion.
There was a time when pharmaceutical companies produced new drugs at a steady rate. They invested in the research and development (R&D) of drugs, occasionally producing ‘blockbusters’ which could treat many people, and making enough profit to inject back into R&D. It took around 10–15 years to develop a drug and, while potential drugs often failed to jump the hurdles of clinical trials, there were enough in the pipeline to keep things going.
But, as we heard at the Open Council meeting last week, now that’s simply not the case: fewer and fewer new drugs are being developed, and it’s taking longer and getting more expensive to produce them. The patents have run out on many blockbuster drugs, meaning that pharma companies generate less revenue to plough back into R&D. And as we learn more about disease, the treatments that are produced are more specific to particular groups of patients, meaning that the markets for individual drugs are smaller. Read more